CL121
CL121 is a Glutaminyl Cyclase inhibitor with an IC50 of 0.07 μM against human sQC and an IC50 of 0.54 μM against human gQC. CL121 reduces the level of pyroglutamate (pE)-modified CD47 on the surface of cancer cells. CL121 exhibits anti-tumor activity against triple-negative breast cancer.
For research use only. We do not sell to patients.
- Formula: C20H21N3O3
- Molecular Weight:351.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
CL121 potently inhibits purified human sQC with an IC50 of 0.07 μM and human gQC with an IC50 of 0.54 μM[1].
CL121 (10-40 μM; 72 h) reduces surface pE-CD47 modification in a dose-dependent manner on MDA-MB-231 cells without affecting total CD47 expression[1].
CL121 (10-40 μM) enhances macrophage-mediated phagocytosis of KYSE30 cells, with the most potent effect at 20 μM, while higher concentrations (40 μM) show reduced activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, KYSE30, MCF-10A, Het1A
-
Concentration:50 μM
-
Incubation Time:72 h
-
Result:Resulted in cell viability above 75% across all tested cell lines.
| Species | Dose | Route | Cmax | Tmax | T1/2 | CLz/F | Vz/F | AUC0-∞ |
|---|---|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | i.p. | 4976 ± 889 μg/L | 0.25 h | 2.48 ± 2.15 h | 1.9 ± 0.4 L/h/kg | 6 ± 3.84 L/kg | 5431 ± 1253 μg/L·h |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; daily; 3 weeks
-
Result:Reduced average tumor volume to 154 mm3 (from 227 mm3 in controls) and average tumor weight to 129.05 mg (from 191.49 mg in controls) at 10 mg/kg, with statistically significant tumor weight reduction (P < 0.01).
Reduced average tumor volume to 195 mm3 and average tumor weight to 173.69 mg at 20 mg/kg, with no statistically significant difference compared to controls.
Significantly reduced intratumoral pE-CD47 expression relative to controls at both doses, with 10 mg/kg showing statistically significant reduction (P < 0.05) and 20 mg/kg showing stronger statistically significant reduction (P < 0.01).
Showed no significant differences in body weight between treatment groups and controls, indicating low systemic toxicity.
Chemical Information
-
Molecular Weight 351.40
-
Formula C20H21N3O3
-
SMILES
COC1=C(C=C(C=C1)NC(C2=CC(CN3C=NC=C3C)=CC=C2)=O)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)